Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2014
06/05/2014WO2014083311A1 Tetracycline topical formulations, preparation and uses thereof
06/05/2014WO2014083229A1 Use of metalloprotease inhibitors for the treatment of polycystic liver diseases
06/05/2014WO2014083177A1 Synbiotic composition and use thereof
06/05/2014WO2014083172A1 Increasing the bioavailability of flavan-3-ols by polyphenols
06/05/2014WO2014083171A1 Natural compounds for use in the treatment of beta-2 adrenergic receptor related diseases
06/05/2014WO2014083166A1 Synbiotic composition and use thereof
06/05/2014WO2014083161A1 Increasing the bioavailability of flavan-3-ols with carbohydrates with a low glycemic index
06/05/2014WO2014083139A1 Novel amorphous form of ticagrelor
06/05/2014WO2014083113A1 Crystallization process of tricyclic indole derivatives
06/05/2014WO2014083107A1 METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
06/05/2014WO2014083099A1 A method of inhibiting the expression of il-22 in activated t-cells
06/05/2014WO2014083095A1 Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression
06/05/2014WO2014083071A1 Injectable liquid formulation of the combination of tramadol and paracetamol
06/05/2014WO2014083068A1 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
06/05/2014WO2014083067A1 Process for the production of discrete solid extruded particles
06/05/2014WO2014083059A1 Use of a dha ester for prophylactic and/or curative treatment of drepanocytosis
06/05/2014WO2014083058A1 Combination therapy with volasertib
06/05/2014WO2014083026A1 Inhibitors of bruton's tyrosine kinase
06/05/2014WO2014083003A1 Pro-cognitive compound
06/05/2014WO2014082960A1 Dermatitis treatment
06/05/2014WO2014082935A1 Cyclic nucleoside derivatives and uses thereof
06/05/2014WO2014082918A1 New indanyloxydihydrobenzofuranylacetic acids
06/05/2014WO2014082889A1 Novel imidazolines as dual inhibitors of mdm2 and mdmx
06/05/2014WO2014082739A1 Substituted amino-arylcarboxamides as kcnq2/3 modulators
06/05/2014WO2014082738A1 Heteroquinoline-3-carboxamides as kcnq2/3 modulators
06/05/2014WO2014082737A1 Specific carboxamides as kcnq2/3 modulators
06/05/2014WO2014082724A1 Aqueous oral solutions of steroid hormones and hydroxypropyl-beta-cyclodextrin with optimised bioavailability
06/05/2014WO2014082651A1 Novel method for improving the bioavailability of low aqueous solubility drugs
06/05/2014WO2014082598A1 Inhibitors of bruton's tyrosine kinase
06/05/2014WO2014082594A1 Neuraminidase inhibitor and pharmaceutical purpose of prodrug thereof
06/05/2014WO2014082592A1 Neuraminidase inhibitor prodrug and composition and use thereof
06/05/2014WO2014082581A1 Α-(3,5-dimethoxy benzylidene)-α'-hydrocarbyl methylene cyclic ketone and preparation method thereof
06/05/2014WO2014082578A1 Heteroaryl alkyne compound and application thereof
06/05/2014WO2014082570A1 Artemether-containing pharmaceutical composition, preparation, and use thereof
06/05/2014WO2014082569A1 Use of artemether in preparation of drug for treating leukemia
06/05/2014WO2014082548A1 2-aryl selenazole compound and pharmaceutical composition thereof
06/05/2014WO2014082544A1 Entacapone for prevention and treatment of obesity and related metabolic diseases
06/05/2014WO2014082381A1 Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
06/05/2014WO2014082380A1 Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
06/05/2014WO2014082379A1 Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
06/05/2014WO2014082354A1 Crystal form of chidamide, preparation method and use thereof
06/05/2014WO2014082286A1 Rafamycin analogs and methods for making same
06/05/2014WO2014082254A1 Inhibitory oligonucleotide and use thereof
06/05/2014WO2014082230A1 Pyrrolotriazine derivative, preparation method thereof and application thereof in medicine
06/05/2014WO2014082163A1 Tox inhibition for the treatment of cancer
06/05/2014WO2014060638A8 A veterinary method of alleviating noise aversion
06/05/2014WO2014059279A3 Materials and methods useful to treat neuroblastomas and pheochromocytomas
06/05/2014WO2014045127A3 Omega-3 phospholipid supplements for females
06/05/2014WO2014043289A3 Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof
06/05/2014WO2014027355A3 Cytotoxic titanium and vanadium complexes
06/05/2014WO2013166037A9 Non-retinoid antagonists for treatment of eye disorders
06/05/2014WO2013160642A3 Wound treatment
06/05/2014WO2013148638A3 Compositions and methods related to inhibitors of jak kinase
06/05/2014WO2013106689A8 Hcv ns3 protease inhibitors
06/05/2014US20140157443 Methods and compositions for detecting and modulating a novel mtor complex
06/05/2014US20140155493 Bis-aromatic anticancer agents
06/05/2014US20140155492 Composition and method for affecting male and female hormone levels
06/05/2014US20140155489 Process for the production of an abuse-proofed solid dosage form
06/05/2014US20140155488 Compositions and methods for stimulating hair growth
06/05/2014US20140155487 Method for correcting a lipid imbalance in a subject
06/05/2014US20140155486 Administration of Iloprost as Aerosol Bolus
06/05/2014US20140155485 Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
06/05/2014US20140155484 Method of treating liver disorders
06/05/2014US20140155483 Edible Oral Strip or Wafer Dosage Form Containing Ion Exchange Resin for Taste Masking
06/05/2014US20140155481 Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
06/05/2014US20140155479 Tiglien-3-one derivatives
06/05/2014US20140155477 Substituted biaryl sulfonamides and the use thereof
06/05/2014US20140155461 Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
06/05/2014US20140155456 Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
06/05/2014US20140155455 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
06/05/2014US20140155450 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
06/05/2014US20140155449 New use of l-histidine and derivatives thereof
06/05/2014US20140155448 Amino-acid-containing composition for enhancing recovery from muscle fatigue
06/05/2014US20140155446 Dexmedetomidine premix formulation
06/05/2014US20140155444 Tetrahydronaphthalene derivatives
06/05/2014US20140155443 Compositions and methods of treatment for psoriasis
06/05/2014US20140155442 Anti-obesity agent comprising high-purity epa
06/05/2014US20140155435 Kit for Treatment of Upper Gastrointestinal Tract Conditions
06/05/2014US20140155433 Biaryl derivatives as nachr modulators
06/05/2014US20140155431 Modulators of atp-binding cassette transporters
06/05/2014US20140155430 Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
06/05/2014US20140155429 Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine
06/05/2014US20140155428 Novel compounds
06/05/2014US20140155427 Novel compounds
06/05/2014US20140155426 Pharmaceutical formulation containing irritant
06/05/2014US20140155425 Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
06/05/2014US20140155424 Naltrexone long acting formulations and methods of use
06/05/2014US20140155421 Substituted pyrimidinyl-pyrroles active as kinase inhibitors
06/05/2014US20140155420 Inhibitors of eya2
06/05/2014US20140155416 Substituted pyrazolo[1,5-a] pyrimidines as calcium receptor modulating agents
06/05/2014US20140155415 Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
06/05/2014US20140155412 Oligomer-diarylpiperazine conjugates
06/05/2014US20140155411 Tuberculosis Biomarkers and Uses Thereof
06/05/2014US20140155409 Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance
06/05/2014US20140155406 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk inhibitors
06/05/2014US20140155405 Concentrated methotrexate solutions
06/05/2014US20140155404 Piperazinylpiperidine derivatives as chemokine receptor antagonists
06/05/2014US20140155401 Novel substituted bipyridine derivatives and their use as adenosine receptor ligands
06/05/2014US20140155399 BRAF Mutations Conferring Resistance to BRAF Inhibitors
06/05/2014US20140155397 Emt signatures and predictive markers and method of using the same
1 ... 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 ... 7860